AC
IDNA icon

AlphaCore Capital’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

AlphaCore Capital’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26 Hold
1
– – ﹤0.01% 1477
2026
Q1 		$23 Hold
1
– – ﹤0.01% 1202
2025
Q4 		$20 Buy
+1
New +$26 ﹤0.01% 1418

Other funds holding IDNA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCore Capital's IDNA Position: Q2 2026 in Review

AlphaCore Capital held its iShares Genomics Immunology and Healthcare ETF (IDNA) position steady in Q2 2026 at 1 share worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #1477.

AlphaCore Capital first reported a position in IDNA in Q4 2025 and has held it in 3 quarters since. 66 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

  • AlphaCore Capital held 1 share of iShares Genomics Immunology and Healthcare ETF worth $26 as of Q2 2026.
  • AlphaCore Capital left its iShares Genomics Immunology and Healthcare ETF share count unchanged in Q2 2026.
  • iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1477 holding.
  • AlphaCore Capital first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2025 and has held it in 3 quarters since.
  • 66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.